PPARA and metabolic dysfunction-associated steatotic liver disease: The thiazolidinediones group, which includes the peroxisome proliferator-activated receptor (PPAR) agonists rosiglitazone and pioglitazone, has anti-steatotic, anti-inflammatory, and to a lesser extent, therapeutic benefits in NAFLD [42].